



Substitute for form 1449A/PTO

**Complete if Known**

*(use as many sheets as necessary)*

Sheet	1	of	Attorney Docket Number	016930-003712US
-------	---	----	------------------------	-----------------

## U.S. PATENT DOCUMENTS+

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>Joan [Signature]</i>	Date Considered	4/26/05
-----------------------	-------------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	of		Attorney Docket Number	016930-003712US
-------	---	----	--	------------------------	-----------------

**Complete if Known**

Application Number	10/086,294
Filing Date	February 28, 2002
First Named Inventor	Nielsen, Loretta
Art Unit	4635 1632
Examiner Name	Lacourciere, K. Hama, J.
Attorney Docket Number	016930-003712US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
gh	AB	Blagosklonny, <i>et al.</i> , "In Vitro Evaluation of A p53-Expressing Adenovirus As An Anti-Cancer Drug," <i>Int. J. Cancer</i> 67:386-392 (1996)	
	AC	Brinckerhoff, <i>et al.</i> , <i>Human Gene Therapy</i> 6:1065-1124 (August 1995)	
	AD	Chang, <i>et al.</i> , "Restoration of the G <sub>1</sub> Checkpoint and the Apoptotic Pathway Mediated by Wild-type p53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy," <i>Arch Otolaryngol Head Neck Surg.</i> , 123:507-512 (1997)	
	AE	Delia, <i>et al.</i> , <i>Nature Medicine</i> 2(7):724-725 (July 1996)	
	AF	Fujiwara, <i>et al.</i> , "Induction of chemosensitivity in human lung cancer cells <i>in Vivo</i> by adenovirus-mediated transfer of the wild-type p53 gene," <i>Cancer Research</i> 54:2287-2291 (1994)	
	AG	Frank, <i>et al.</i> , "Combination E2F-1 and p53 Gene Transfer Does Not Enhance Growth Inhibition in Human Squamous Cell Carcinoma of the Head and Neck," <i>Clin. Cancer Research</i> 4:2265-2272 (1998)	
	AH	Gallardo, <i>et al.</i> , "Adenovirus-based Transfer of Wild-Type p53 Gene Increases Ovarian Tumor Radiosensitivity," <i>Cancer Research</i> 56:4891-4893 (1996)	
	AI	Gjerset, <i>et al.</i> , "Use of Wild-Type p53 to Achieve Complete Treatment Sensitization of Tumor Cells Expressing Endogenous Mutant p53," <i>Molecular Carcinogenesis</i> 14:275-285 (1995)	
	AJ	Gurnani, <i>et al.</i> , "Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer," <i>Cancer Chemother Pharmacol.</i> 44:143-151 (1999)	
	AK	Hehir, <i>et al.</i> , <i>Journal of Virology</i> 70(12):8459-8467 (December 1996)	
	AL	Kalechman, <i>et al.</i> , <i>Journal of Immunology</i> 156(3):1101-1109 (1996)	
	AM	Nguyen, <i>et al.</i> , "Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer," <i>J. Thorac. Cardiovasc. Surg.</i> 112:1372-1377 (1996)	
✓	AN	Nielsen, <i>et al.</i> , "Adenovirus-mediated p53 Gene Therapy and Paclitaxel Have Synergistic Efficacy in Models of Human Head and Neck, Ovarian, Prostate, and Breast Cancer," <i>Clin. Cancer Research</i> 4:835-846 (1998)	

Examiner Signature	<i>Joan ID</i>	Date Considered	4/26/05
--------------------	----------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	3	of		<b>Complete if Known</b>	
				Application Number	10/086,294
				Filing Date	February 28, 2002
				First Named Inventor	Nielsen, Loretta
				Art Unit	1635-1632
				Examiner Name	Lacoursiere, K. Hama, J.
				Attorney Docket Number	016930-003712US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
gt	AO	Ogawa, <i>et al.</i> , "Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent," <i>Int. J. Cancer</i> 73:367-370 (1997)	
	AP	Parsels, <i>et al.</i> , "Prevention of Fluorodeoxyuridine-Induced Cytotoxicity and DNA Damage in HT29 Colon Carcinoma Cells by Conditional Expression of Wild-Type p53 Phenotype," <i>Molecular Pharmacology</i> 52:600-605 (1997)	
	AQ	Pirollo, <i>et al.</i> , "p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy," <i>Oncogene</i> , 14:1735-1746 (1997)	
	AR	Sandig, <i>et al.</i> , "Adenovirally transferred <i>p16<sup>INK4/CDKN2</sup></i> and <i>p53</i> genes cooperate to induce apoptotic tumor cell death," <i>Nature Med.</i> , 3:313-319 (1997)	
	AS	Spitz, <i>et al.</i> , "In Vivo Adenovirus-Mediated p53 Tumor Suppressor Gene Therapy for Colorectal Cancer," <i>Anticancer Research</i> , 16:3415-3422 (1996)	
	AT	Spitz, <i>et al.</i> , "Adenoviral-mediated Wild-Type p53 Gene Expression Sensitizes Colorectal Cancer Cells to Ionizing Radiation," <i>Clin. Cancer Research</i> 2:1665-1671 (1996)	
	AU	Son, <i>et al.</i> , "Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer," <i>Proc. Natl. Acad. Sci. USA</i> , 91:12669-12672 (1994)	
	AV	Tishler, <i>et al.</i> , <i>British Journal of Cancer</i> 74(27):S82-S85 (1996)	

60142442 v1

Examiner Signature	<i>Joan Ida</i>	Date Considered	4/26/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

60142442 v1

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	10/086,294
Filing Date	February 28, 2002
First Named Inventor	Nielsen, Loretta
Art Unit	1635 1632
Examiner Name	Lacourciere, K. Hama, J.
Attorney Docket Number	016930-003712US

[illegible][illegible]

**Examiner  
Signature**

to en th

Date Considered

4126105

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60414139 v1

SEP 30 2005

**(use as many sheets as necessary)**

Sheet	2	of	2
-------	---	----	---

Application Number	10/086,294
Filing Date	February 28, 2002
First Named Inventor	Nielsen, Loretta
Art Unit	<del>1635</del> 1632
Examiner Name	Lacourciere, K. Hama, J.
Attorney Docket Number	016930-003712US

[illegible]

Joan Lee

4126105

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	10/086,294
		Filing Date	February 28, 2004
		First Named Inventor	Nielsen et al.
		Art Unit	1035-1632
		Examiner Name	Lacourciere, K. Hama, J
Sheet 3 of 3	Attorney Docket Number	016930-003712US	

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
gt	AA	WO	95/10514	A1	04-20-1995	Schering Corp.		<input type="checkbox"/>
↓	AB	WO	95/28948	A1	11-02-1995	Univ. Texas		<input type="checkbox"/>
↓	AC	WO	97/23478	A1	07-03-1997	Schering Corp.		<input type="checkbox"/>
								<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
gt	AD	HARRIS et al., "Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies" <i>J. Natl. Cancer Inst.</i> (1996) 88(20):1442-1455.	
↓	AE	NIELSEN et al., "Combination therapy with the Farnesyl protein transferase inhibitor SCH86338 and SCH58500 (p53 Adenovirus) in preclinical cancer models" <i>Cancer Research</i> (1999) 59:5896-5901.	
↓	AF	TISHLER et al., "Microtubule-active drugs Taxol, Vinblastine, and Nocodazole increase the levels of transcriptionally active p53" <i>Cancer Research</i> (1995) 55:6021-6025.	

60235769 v1

Examiner Signature	Joan Ida	Date Considered	4/26/05
--------------------	----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

60235769 v1